Texas Medical Center
The Woodlands, TX 77384
Ricardo J. Flores, MD
Dr. Ricardo J. Flores graduated from University of Puerto Rico School of Medicine with highest honors in 2004. He completed his training in Pediatrics at the University of Puerto Rico Pediatric Hospital in 2007, and his subspecialty training in pediatric hematology/oncology at Baylor College of Medicine and the Texas Children’s Cancer and Hematology Centers in 2010.
While in medical school, Dr. Flores experienced the death of a very close family member who truly struggled against an aggressive type of leukemia. From this, he recognized that treating patients with cancer and blood diseases required an extremely concerted effort from family and health care providers, and decided to train in the field of hematology/oncology, which encompasses all aspects of the medical profession.
During his initial year of hematology/oncology training, Dr. Flores became interested in pediatric bone tumors, especially in the patients who presented with aggressive disease and had limited treatment options. At that time, he resolved to focus his research efforts on the high-risk bone tumor pediatric patients.
Beyond his clinical and research duties, Dr. Flores is actively involved in ongoing efforts to promote and advance underrepresented minorities in the fields of Science, Technology, Engineering, and Mathematics (STEM-fields). In 2010, the American STEM Association selected him as member of the Leadership Institute Training Program for the Advancement of Science. In 2011, he was invited to serve as Master of Ceremonies for the Society on the Advancement of Science Chicanos/Hispanics and Native Americans National Conference, with over 3,000 participants, including Nobel Prize and National Medal of Science recipients. As a result of his scientific and outreach work, he was selected as a 2012 distinguished young physician scientist and interviewed by the National Library of Medicine for their “Career Pathways” video library. He has also been highly involved with mass media health education, and has participated on dozens of interviews on nationwide radio, newspapers, and TV networks, including Telemundo, Univision and PBS, among others.
Since October 2016, Dr. Flores-Hernández has been the Clinical Director of Pediatric Hematology-Oncology at the Texas Children’s Hospital’s Woodlands location.
His research efforts focus on high-risk bone tumors in pediatric patients.
After completing his training, Dr. Flores was supported by the National Institutes of Health’s National Cancer Institute (NIH-NCI) to continue his research on pediatric bone tumors, cancer biomarkers, and novel therapeutic targets for high-risk pediatric cancer patients. Since 2008, he has applied state-of-the-art technologies and novel informatics approaches that have resulted in significant findings and progress regarding personalized cancer treatment. His research has been published in various peer review medical journals including Cancer, Pediatric Blood and Cancer, and BMC Systems Biology. And, he has presented at national and international meetings, such as the American Association of Cancer Research (AACR), the Cancer Education Consortium (CEC), and the Cancer Prevention & Research Institute of Texas (CPRIT). He has also served as the co-editor of several cancer research and clinical books. In 2016, the NIH highlighted Dr. Flores efforts as an example of excellent cancer research.
Dr. Ricardo Flores previously conducted clinical research on Langerhan's cell histiocystosis with Dr. Kenneth McClain and Dr. Carl Allen for the Histiocytosis Program at Texas Children’s Cancer Center.
Dr. Ricardo Flores also worked in the laboratories of Dr. Ching Lau and Dr. Chris Tsz-Kwong Man. In Dr. Man’s laboratory he researched the use of a tumor-targeted approach to identify metastatic biomarkers in osteosarcoma tumor cells, followed by the confirmation of biomarkers in plasma using proteomic and computational approaches.
R Flores, AJ Kelly, Y Li, M Nakka, DA Barkauskas, M Krailo, LL Wang, L Perlaky, CC Lau, MJ Hicks, TK Man. A novel prognostic model for osteosarcoma using circulating CXCL10 and FLT3LG. Cancer, August 16, 2016 doi: 10.1002/cncr.30272 https://www.ncbi.nlm.nih.gov/pubmed/27529817
R Flores, Y Li, A Yu, J Shen, PH Rao, SS Lau, M Vannucci, CC Lau, T-K Man. A Systems Biology Approach Reveals Common Metastatic Pathways in Osteosarcoma. Open Access: BMC Syst Biol, 2012. 6(1):50, 2012. http://www.biomedcentral.com/1752-0509/6/50/abstract. Highly Accessed by BioMed Central, categorized July 2, 2012.
Y Li and R Flores, A Yu, MF Okcu, J Murray, M Chintagumpala, J Hicks, CC Lau, T-K Man. “Elevated Expression of CXC Chemokines in Pediatric Osteosarcoma Patients.” Cancer, Vol 117(1): 207-217, 2010. PIMD: 20806347
R Flores, L Wang. “Secondary Osteosarcoma,” In: Osteosarcoma, (Vol. 1) Editorial Alfil, S.A. de C.V., Insurgentes Centro 51-A, Col. San Rafael 06470, Mexico D.F., 2014. http://editalfil.com/300-osteosarcoma.html
R Flores, T-K Man (eds). Proteomics: Human Diseases and Protein Functions (1st edition), Vol 3. InTech - Open Access Publisher, Rijeka, Croatia. 2012. http://www.intechopen.com/books/proteomics-human-diseases-and-protein-functions
Star Faculty Award for Excellence in Patient Care, Baylor College of Medicine, 2019
* Texas Children's Hospital physicians' licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician's office and were not verified by Texas Children's Hospital.